Analysts see over 50% gains in these 2 mid-cap biotech stocks

Key PointsOver the last three months, U.S. biotech stocks are up approximately 15% and have outperformed the broader healthcare sector.Last week, biopharma company Madrigal Pharmaceuticals received a bullish endorsement from five analysts after publishing positive clinical trial results.Given Beam Therapeutics’ advancing pipeline and potential to reshape the gene editing landscape, its stock has returned to traders’ radar.5 stocks we like better than Madrigal Pharmaceuticals2024 is shaping up to be a pivota ...